The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

RegeneRx Receives Notice of Allowance for Key US Patent

04-Aug-2016 | Source : RegeneRx Biopharmaceuticals Inc | Visits : 5295
ROCKVILLE, Md. - RegeneRx Biopharmaceuticals Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced in a press release that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient.  The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4 in a pharmacologically effective range.  The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.

"This is an important patent for RegeneRx as it is expected to provide expanded coverage and extended exclusivity for the administration of Tβ4 for the treatment of patients with cardiac and central nervous disorders, which are areas of significant interest for the Company.  Management and patent counsel have worked hard on obtaining this patent and it is a significant achievement under our complex and ever-changing patent laws," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.    

Related Articles